Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors
Open Access
- 17 August 2007
- Vol. 110 (7), 1542-1550
- https://doi.org/10.1002/cncr.22961
Abstract
BACKGROUND. Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children. Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors. METHODS. Temozolomide was administered orally as monthly 5‐day courses at doses of 200 mg/m2/d (patients with no prior craniospinal irradiation [CSI]) or 180 mg/m2/d (prior CSI). Patients with a complete (CR) or partial (PR) response or stable disease (SD) could continue temozolomide for up to 12 cycles. RESULTS. The cohort comprised 122 patients, including 113 with CNS tumors. Median age was 11 years (range, 1–23 years). Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed. PRs occurred in 1 of 23 evaluable patients with high‐grade astrocytoma, 1 of 21 with low‐grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET). The CR occurred in an additional patient with medulloblastoma/PNET. No responses were observed in patients with ependymoma, brain‐stem glioma, or other CNS tumors. Notably, 41% of patients with low‐grade astrocytoma had SD through 12 courses. The most frequent toxicities were grade 3 or 4 neutropenia (19%) and thrombocytopenia (25%); nonhematologic toxicity was infrequent. CONCLUSIONS. Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low‐grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Temozolomide in Children with progressive low-grade glioma1Neuro-Oncology, 2007
- Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO StudyJournal of Clinical Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapyNeuro-Oncology, 2002
- Radiotherapy for medulloblastoma in children: A perspective on current international clinical research effortsMedical and Pediatric Oncology, 2002
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomideAnti-Cancer Drugs, 1999
- In vitro evaluation of temozolomide combined with X-irradiationAnti-Cancer Drugs, 1997
- The charing cross hospital experience with temozolomide in patients with gliomasEuropean Journal of Cancer, 1996
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal of Cancer, 1993